Clinical trials involving over 900 participants showed AOD-9604 to be well-tolerated with side effects indistinguishable from placebo in most studies
Alpha Rejuvenation is not responsible for any errors or omissions in content
The clinical drug development program was halted in 2007 after the pivotal Phase IIb trial did not show statistically significant weight loss in the primary endpoint
doi: 10.3389/fphar.2025.1602976 Received 30 March 2025 Revised 13 November 2025 Accepted 14 November 2025 Published 19 December 2025 Volume 16 - 2025 Edited by Bernd Rosenkranz, Fundisa African Academy of Medicines Development, South Africa Reviewed by Kacper Nijakowski, Poznan University of Medical Sciences, Poland Miriam Njoki Karinja, Science for Africa Foundation, Kenya Updates Copyright 2025 Mazur, Ndokaj, Salerno, Vallone, Ardan, Bietolini, Carrouel, Wilk, Sarig, Ottolenghi and Bourgeois